Sidvim LifeSciences Private Limited

Q1 2026 API & IP Insights: DMF Filings, GLP-1 Litigation, and Major Patent Revocations The first quarter of 2026 has seen a significant shift in the pharmaceutical landscape, with 379 new Type II DMFs filed at the USFDA. While Indian and Chinese companies continue to dominate the volume of filings, the focus has moved sharply toward Complex APIs and New Oncology molecules, such as Fruquintinib and Tirzepatide. For industry professionals, these filings represent the first clear roadmap for generic competition in the coming decade. 1. Q1 2026 DMF Filing Trends: India and China Lead the Charge The USFDA recently released the DMF filing list for the first quarter of 2026, revealing a total of 379 Type II DMFs submitted. The data shows a clear dominance by Indian and Chinese manufacturers, particularly in the "New APIs" and "Speciality" categories.   Breakdown by Category:    New APIs / Speciality: ~160 DMFs from India; ~136 from China.   Complex APIs: 18 fi...

Introduction The pharmaceutical landscape is rapidly evolving with strategic P-IV challenges and complex generic developments. Our latest newsletter explores critical updates from the FDA website (as of April 13, 2026) and a significant Delhi High Court judgment that could set a precedent for future pharmaceutical infringement damages in India. Recent Paragraph IV (P-IV) Filings: Strategic Market Entries Generic manufacturers are increasingly targeting high-value orphan drugs and complex formulations to bypass long-term patent barriers. 1. Nusinersen (Spinraza) - Complex Generic Challenge Drug Profile: An antisense oligonucleotide (ASO) for Spinal Muscular Atrophy (SMA). The Opportunity: While 2023 US sales were approximately $500 million, the innovator recently secured a new high-dose regimen approval on March 30, 2026, to shift the patient base before the 12 mg version goes generic. Key Players: Industry analysis suggests potential involvement from Indian firms like Natco and Cipla. ...

API and IP News Update: 2026 Pharmaceutical Trends & Legal Rulings This comprehensive update covers the latest CDSCO approvals, significant pharmaceutical trademark litigation in India, and pivotal EPO patent decisions impacting biotechnology and precision medicine. New CDSCO & DCGI Approvals (Q1 2026) The first quarter of 2026 has seen major regulatory milestones in the Indian healthcare market, specifically within neuropsychiatry and oncology. Brexpiprazole: Expanding Neuropsychiatry Access On February 16, 2026, the DCGI approved Brexpiprazole tablets, a second-generation atypical antipsychotic. Indication: Primarily used for schizophrenia, with future potential for MDD and Alzheimer ’s-related agitation. Market Impact: With the Indian patent (IN 251204) expiring on April 12, 2026, the pathway is clear for affordable generic entry. Key Players: Torrent Pharmaceuticals is a lead contender following successful Phase III trials, while MSN Laboratories secured bulk drug ...